Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2023 01:00 ET | Source: Pharming Group N.V.

Pharming Group reports third quarter 2023 financial results

Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and...
October 12, 2023 02:00 ET | Source: Pharming Group N.V.

Pharming Group to report third quarter 2023 financial results on October 26

Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial...
September 25, 2023 10:00 ET | Source: Pharming Group N.V.

Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders...
March 06, 2014 01:13 ET | Source: Pharming Group N.V.

Pharming Reports On Preliminary Financial Results 2013

LEIDEN, Netherlands, March 6, 2014 (GLOBE NEWSWIRE) -- Revenues and other income decreased to €7.0 million (2012: €10.9 million) mainly as a result from lower license fees as 2012...
February 24, 2014 01:12 ET | Source: Pharming Group N.V.

PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)

LEIDEN, Netherlands and RALEIGH, N.C., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Pharming Group NV (NYSE Euronext:PHARM) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Food and Drug...
November 08, 2013 01:06 ET | Source: Pharming Group N.V.

PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR)

LEIDEN, Netherlands and SAN DIEGO, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) announced that new data from an open-label extension of...
November 07, 2013 01:10 ET | Source: Pharming Group N.V.

Pharming Reports On Financial Results For The First Nine Months Of 2013

LEIDEN, Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the first nine...
October 09, 2013 01:07 ET | Source: Pharming Group N.V.

Pharming announces EU12.0 million private equity placement with institutional investors

LEIDEN, Netherlands, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has entered into a private...
August 17, 2006 12:58 ET | Source: Pharming Group N.V.

Pharming's Marketing Authorization Application for Rhucin -- RHC1INH -- Accepted for Review by EMEA

LEIDEN, Netherlands, Aug. 17, 2006 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming") (Euronext:PHARM) (PHARM.AS) announced today that its Marketing Authorization Application (MAA) for...
November 17, 2005 02:13 ET | Source: Pharming Group N.V.

Pharming Presents rhC1INH Update at International Meetings

LEIDEN, Netherlands, Nov. 17, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that the Company presented clinical...